title: Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma.
abstract: The present study was conducted to evaluate activity and toxicity of the FLEC (folinic acid 100 mg/m2; 5-fluorouracil 1000 mg/m2; carboplatin 300 mg/m2; epirubicin 60 mg/m2) schedule as second-line treatment for progressive locally advanced or metastatic pancreatic cancer (LAMPC). FLEC was administered every 3 weeks with an angiographic catheter introduced into the tumor vascular bed. Thirty-two patients were enrolled. Twenty patients had a PS of 2. Twenty-five patients had metastatic disease to liver. Seven (21.9%) partial responses were observed (WHO criteria). Fifteen patients (46.9%) had stable disease and ten patients (31.2%) had progressive disease. The median OS from the diagnosis was 11.8 months. PS (p=0.0308) and pain (WHO scale, p=0.0222; analogic scale, p=0.0446) significantly improved after therapy. No patient discontinued treatment because of toxicity (NCI-CTC criteria). The current study shows that intraarterial chemotherapy is a good therapeutic option in second-line treatment of LAMPC.
authors.affiliation: Department of Oncology, G. Rummo Hospital, 82100, Benevento, Italy. emiddiobarletta@libero.it
authors.forename: Emiddio
authors.initials: E
authors.lastname: Barletta
authors.forename: Francesco
authors.initials: F
authors.lastname: Fiore
authors.forename: Bruno
authors.initials: B
authors.lastname: Daniele
authors.forename: Alessandro
authors.initials: A
authors.lastname: Ottaiano
authors.forename: Roberto
authors.initials: R
authors.lastname: D'Angelo
authors.forename: Ettore
authors.initials: E
authors.lastname: Ferrari
authors.forename: Roberta
authors.initials: R
authors.lastname: Formato
authors.forename: Anna
authors.initials: A
authors.lastname: Tortoriello
authors.forename: Giacinto
authors.initials: G
authors.lastname: Turitto
authors.forename: Giovanni Salvatore
authors.initials: GS
authors.lastname: Bruni
authors.forename: Sandro
authors.initials: S
authors.lastname: Pignata
authors.forename: Rosario Vincenzo
authors.initials: RV
authors.lastname: Iaffaioli
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001835:Body Weight; D016190:Carboplatin / Q000627:therapeutic use; D018450:Disease Progression; D015251:Epirubicin / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007261:Infusions, Intra-Arterial; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D015251:Epirubicin; D016190:Carboplatin; D002955:Leucovorin; D005472:Fluorouracil